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Abstract
In chronic obstructive pulmonary disease (COPD), acute exacerbation of COPD requiring
hospital admission is associated with mortality and healthcare costs. The ERICA study
assessed multiple clinical measures in people with COPD, including the short physical per-
formance battery (SPPB), a simple test of physical function with 3 components (gait speed,
balance and sit-to-stand). We tested the hypothesis that SPPB score would relate to risk of
hospital admissions and length of hospital stay. Data were analysed from 714 of the total
729 participants (434 men and 280 women) with COPD. Data from this prospective observa-
tional longitudinal study were obtained from 4 secondary and 1 tertiary centres from
England, Scotland, and Wales. The main outcome measures were to estimate the risk of
hospitalisation with acute exacerbation of COPD (AECOPD and length of hospital stay
derived from hospital episode statistics (HES). In total, 291 of 714 individuals experienced
762 hospitalised AECOPD during five-year follow up. Poorer performance of SPPB was
associated with both higher rate (IRR 1.08 per 1 point decrease, 95% CI 1.01 to 1.14) and
increased length of stay (IRR 1.18 per 1 point decrease, 95% CI 1.10 to 1.27) for hospital-
ised AECOPD. For the individual sit-to-stand component of the SPPB, the association was
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even stronger (IRR 1.14, 95% CI 1.02 to 1.26 for rate and IRR 1.32, 95% CI 1.16 to 1.49 for
length of stay for hospitalised AECOPD). The SPPB, and in particular the sit-to-stand com-
ponent can both evaluate the risk of H-AECOPD and length of hospital stay in COPD. The
SPPB can aid in clinical decision making and when prioritising healthcare resources.
Introduction
In the United Kingdom (UK), chronic obstructive pulmonary disease (COPD) related mortal-
ity and healthcare costs are projected to increase significantly, with annual direct healthcare
costs in England alone expected to increase from £1.5 billion in 2011 to £2.32 billion by 2030.
[1] Most of the cost of treating COPD arises from inpatient care,[2] specifically for hospitalised
acute exacerbations (i.e. episodic worsening of symptoms) of COPD (H-AECOPD).
According to 2016–17 statistics of the National Health Services (NHS) Digital, more than
128,000 individuals with a specific code for COPD exacerbation in the United Kingdom were
admitted to hospital, of which 97% were emergency admissions with a median hospital length
of stay of three days.[3] Leaving aside cost, admission with AECOPD is a major event in the
lifetime of a COPD patient. National UK audit data shows that, while outcomes have
improved, in-patient mortality remains high (4.3%) with a further 2.8% of those discharged
dying within 30 days. Importantly, longer length of stay was associated with increased mortal-
ity at both 30 and 90 days (9.9 and 22.6% respectively).[4]
The risk of having an acute exacerbation of COPD is determined by the patient’s contact
with an infectious (i.e. bacterial or viral) or environmental (e.g. air pollution) triggers. How-
ever, the need for hospitalisation for AECOPD is also determined by the patient’s physical
capacity. In a prior analysis of data from the COPD Biomarker Qualification Consortium,[5]
we showed that an integrative test of physical capacity, the six minute walk test (6MWT) dis-
tance, was not at all predictive of the likelihood of acute exacerbation but was strongly predic-
tive of one year mortality and to a lesser extent of hospitalisation.
The 6MWT is cumbersome in general practice and to some extent in secondary care; this is
acknowledged in the recent update of the National Institute for Health and Care Excellence
2018 guidelines that recommended against the use of the BODE Index for prognostication
since the components (which include 6MWT) are time-intensive and seldom feasible in pri-
mary care.[6] In particular, the 6MWT requires a minimum 30m flat, uninterrupted track in
an unhurried setting, which is often unavailable, and when completed properly should be
undertaken twice to minimise learning effect. Thus, a proper evaluation may take 30 minutes.
In contrast, the short physical performance battery (SPPB) can be undertaken with no special
facilities in a routine clinic and is used in clinical practice by geriatricians and those in pulmo-
nary rehabilitation.[7]
We therefore hypothesised in this study that SPPB score could serve both to identify
patients who are more likely to be hospitalised or, when admitted, to have a longer length of
stay. Data from the UK multicentre Evaluating the Role of Inflammation in Chronic Airways
disease (ERICA) cohort study, which has been described in more detail elsewhere[8,9] were
used with the aim being to evaluate the relationship between functional measures, specifically
SPPB and risk of H-AECOPD. Further, we aimed to determine a relationship with length of
hospital stay for initial (i.e. first hospital admission after assessment) AECOPD. To address
these questions, we combined routinely collected hospital electronic health record data with
baseline ERICA data.
Risk assessment for hospitalised AECOPD
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Methods
Study design and participants
Observational data is reported according to the STROBE statement.[10] Data were used from
the ERICA cohort, a multi-centre observational, non-interventional, epidemiological study
with a sample size of 729 individuals with stable COPD (Global Initiative for Chronic Obstruc-
tive Lung Disease grade II-IV). The study was originally designed and powered on the basis of
a tertile analysis of variables pulse wave velocity and QMVC, based on an estimated sample
size of 800 individuals with COPD. Full study design and participant details are available in
the published ERICA cohort protocol.[8] The study is registered with the UK Clinical Research
Network Study Portfolio (StudyID 11101). Baseline data were collected between December
2011 and January 2014. Patient level cohort data were linked to hospital admission data
obtained from the NHS admitted patient care dataset, Hospital Episodes Statistics (HES) in
England, Scotland and Wales, which captures all H-AECOPD, since cohort baseline visit until
November 2017. Analyses were limited to a maximum five years of follow-up. See S1 Text for
further details.
Study outcomes
The primary outcome measure was H-AECOPD. These data were first cleaned for episode sta-
tus and inpatient (i.e. hospitalised) AECOPD episodes were identified using validated criteria
(S1 Table).[11] Acute exacerbations of COPD were extracted from both primary and second-
ary positions of international classification of diseases and related health problems 10th revi-
sion coding. Only so-called definite and possible H-AECOPD were considered for this
analysis. Only episodes during the study follow-up were evaluated. Admission and discharge
dates were used to determine hospital length of stay (i.e. number of days) for initial
H-AECOPD after ERICA assessment.
Potential predictor variables
All significant variables reported by Hurst et al.[12] and functional measures assessed in the
ERICA cohort were considered. A full list of predictor variables is shown in S2 Table including
demographics, lung function measurements, blood markers, health-related quality of life and
respiratory symptoms questionnaire data, and functional assessments. Measures of particular
interest were those measuring physical capacity including SPPB and its components (i.e.
4-metre gait speed (4MGS), balance, and 5 repetition sit-to-stand), quadriceps maximum vol-
untary contraction (QMVC), and 6MWT. The SPPB is a battery of tests and used to evaluate
the physical performance of the lower extremities. Its three components score 0–4. Total SPPB
score is the sum of points of each component, with a maximum of twelve denoting no func-
tional limitation. QMVC is a surrogate marker of functional activity (i.e. quadriceps muscle
strength) where the best effort of six contractions was recorded, and the QMVC%predicted was
derived from the Seymour equation.[13] The 6MWT was used to assess exercise intolerance
and to evaluate functional exercise capacity by recording the distance walked as quickly as pos-
sible for six minutes. The exacerbation history in the twelve months prior to study baseline
was dichotomised (i.e. 0 vs.� 1). Prior exacerbation history was self-reported and defined as
requiring treatment with oral steroids or antibiotics.
Statistical analysis
Missing values are described in S1 and S2 Figs, S2 Text; only complete cases were considered.
Relationships between baseline variables were quantified using Spearman’s pair-wise
Risk assessment for hospitalised AECOPD
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correlations; values< 0.30 were considered weak, 0.30–0.50 as moderate, and> 0.50 as strong
(S3 Fig).[14] Negative binomial regression was used to examine the association between func-
tional measures and (i) the rate of H-AECOPD within the study period, and (ii) length of hos-
pital stay (per day). Analyses were adjusted for exposure times (time between baseline visit
date and earliest of death, or end of study period). Regression estimates are presented as inci-
dence-rate ratios (IRR). Incidence risk ratios for log-transformed biomarkers represent a two-
fold increase in the biomarker.
All analyses were stratified by recruitment site and adjusted for age and sex. Further analy-
ses were adjusted for body mass index, smoking status, and covariates found to be of signifi-
cance in the main multivariate model by Hurst et al, namely exacerbation history (previous
year), forced expiratory volume in one second (FEV1) measured in litres, and productive
cough (defined using questionnaire data: “If you cough, do you produce phlegm (sputum)?”).
[12] Covariates were tested for collinearity resulting in the omission of Medical Research
Council dyspnoea score and white cell count. Predictors for the final analyses were derived
sequentially, firstly estimating the association of each individual variable fully adjusted, follow-
ing stepwise regression including the significant variables only, whilst considering collinearity
and clinical utility.
In stepwise regression analysis, only predictors with a significance level above α 0.1 for
backward selection and α 0.05 for forward stepwise selection were considered. For each step-
wise regression, likelihood ratio tests were conducted to determine if independent variables
should remain in the analysis or not, and the maximum number of variables considered in
each regression analysis were based on the least number of events.[15] As sex and exacerbation
history can act as effect modifiers, in sensitivity analyses, we explored analysis stratified by
these factors and tested for interactions.
To evaluate the ability of SPPB, or its sit-to-stand component, to predict time to
H-AECOPD, we used Cox-regression with significance assessed using log-rank test for trend.
Estimates are displayed using Kaplan-Meier plots.
All tests were two-sided and of statistical significance level of p = 0.05. Our analyses were
performed using Stata version 13 (College Station, Texas) and R (R Foundation).
Results
Descriptive statistics
In total, 714 individuals with stable COPD and complete data were included in the analysis. At
baseline, the mean ± standard deviation age of the cohort was 67 ± 8 years with 61% of partici-
pants being male. A third of the cohort was overweight, another third obese; and a third were
current smokers. Exacerbations during the year prior to baseline were self-reported by 67%
individuals with a corresponding mean of 2 ± 2 events per person-year. Mean FEV1% pre-
dicted was 52 ± 16%. About half of the cohort (51%) experienced breathlessness that limited
daily activities (Medical Research Council dyspnoea score� 3) and 46% had productive cough
on most mornings (Table 1 and S3 Table, S2 Text). Individuals with a history of AECOPD at
baseline were more likely to be younger, female, have worse lung function, shorter walking dis-
tance, and lower SPPB scores.
In total, 291 (41%) experienced at least one H-AECOPD during the study follow-up; 159
(22%) had multiple events (S4–S6 Figs). Overall, 127 (18%) individuals died and of these, the
majority 103 (81%) died following discharge having been hospitalised for AECOPD during the
study period. Median (interquartile range (IQR)) length of hospital stay for initial (i.e. first
hospital admission after assessment) H-AECOPD was 3 (1–7) days. For the 159 readmitted,
the median time to hospital readmission was 179 (54–421) days, of whom 65 individuals
Risk assessment for hospitalised AECOPD
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(41%) were readmitted to hospital within 90 days after initial admission and had a median
length of stay of 3 (2–7) days.
Table 1. Baseline characteristics.
Total Without AECOPD history at baselinea With AECOPD history at baseline a P value
Characteristic Mean ± SD or n (%)
Description
Age (years) 67 ± 8 68 ± 8 67 ± 7 0.022
Sex, n (%) < 0.001
Male 434 (61) 171 (72) 261 (55)
Female 280 (39) 65 (28) 212 (45)
Body mass index (kg/m2) 27 ± 6 27 ± 5 27 ± 6 0.389
Musculoskeletal measures
6MWT distance (metre) 346 ± 130 384 ± 122 326 ± 130 < 0.001
SPPB (0–12) 10 ± 2 10 ± 2 9 ± 3 0.015
4MGS score (0–4) 4 ± 1 4 ± 1 3 ± 1 < 0.001
Balance points (0–4) 4 ± 1 4 ± 1 4 ± 1 0.719
Sit-to-stand score (0–4) 2 ± 1 3 ± 1 2 ± 1 0.004
QMVC peak (kg) 31 ± 11 29 ± 12 33 ± 11 < 0.001
QMVC % predicted 44 ± 8 46 ± 8 44 ± 8 0.005
Lung function
FEV1% predicted 52 ± 16 57 ± 14 50 ± 16 < 0.001
Smoking status, n (%) 0.032
Current 218 (31) 85 (36) 133 (28)
Former 492 (69) 151 (64) 340 (72)
GOLD, n (%) < 0.001
Grade II 406 (57) 166 (70) 237 (50)
Grade III 240 (34) 56 (24) 183 (39)
Grade IV 68 (10) 14 (6) 53 (11)
Productive cough, n (%) < 0.001
Never 46 (7) 32 (14) 14 (3)
Other 662 (94) 200 (86) 459 (97)
Biochemical measures
log Glucose (mmol/L) 1.60 ± 0.15 1.61 ± 0.16 1.61 ± 0.15 0.945
log Fibrinogen (g/dL) 1.22 ± 0.23 1.18 ± 0.23 1.24 ± 0.23 0.002
log C-reactive protein (mg/L) 1.26 ± 1.08 1.11 ± 1.03 1.32 ± 1.09 0.016
GFR (mL/min/1.73 m2) 88 ± 18 87 ± 19 89 ± 18 0.443
Neutrophil count (mm3) 4.75 ± 1.70 4.57 ± 1.65 4.81 ± 1.67 0.015
Cardiovascular status
Heart rate (bpm) 75 ± 13 74 ± 12 75 ± 12 0.546
Questionnaires
SGRQ-C (0–100) 50 ± 21 40 ± 20 54 ± 20 < 0.001
CAT (0–40) 20 ± 8 17 ± 8 21 ± 8 < 0.001
Values are given as the mean and standard deviation, or No. of cases (%). Baseline data of study participants are included.
aSelf-reported prior to study.
SD, standard deviation. 6MWT, six-minute walk test. SPPB, short physical performance battery. 4MGS, four-metre gait speed. QMVC, quadriceps maximum voluntary
contraction. FEV1, forced expiratory volume in one second. GOLD, global initiative for obstructive lung disease. GFR, glomerular filtration rate. SGRQ-C, St George’s
respiratory questionnaire for COPD. CAT, COPD assessment test.
https://doi.org/10.1371/journal.pone.0228940.t001
Risk assessment for hospitalised AECOPD
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Factors associated with rate of H-AECOPD
Adjusted analysis showed 6MWT, SPPB and its 4MGS, and sit-to-stand components, and
QMVC were all associated with a higher risk of H-AECOPD (Fig 1 and S7 Fig, S4 Table). The
6MWT (IRR 1.13 per 30 metre decrease, 95% CI 1.08 to 1.17, p< 0.001), FEV1 (IRR 0.84 per
100 ml increase, 95% CI 0.81 to 0.86, p< 0.001) or disease severity measured by Global Initia-
tive for Chronic Obstructive Lung Disease (IRR 2.51 per increase to next stage, 95% CI 2.04 to
3.10, p< 0.001), and males (IRR 2.41, 95% CI 1.77 to 3.29, p< 0.001) had the strongest associ-
ated IRRs.
Fully adjusted multivariable stepwise regression retained the following significant predic-
tors: male gender (IRR 2.14, 95% CI 1.55 to 2.96, p< 0.001), FEV1, (IRR 0.88 per 100 ml
increase, 95% CI 0.85 to 0.91, p< 0.001), exacerbation history� 1 (IRR 1.96, 95% CI 1.39 to
2.76, p< 0.001), COPD assessment test score (IRR 1.03 per 1 point increase, 95% CI 1.01 to
1.05, p = 0.010), resting heart rate (IRR 1.01 per 1 bpm increase, 95% CI 1.00 to 1.03,
p = 0.025), and 6MWT (IRR 1.08 per 30 metre decrease, 95% CI 1.04 to 1.12, p< 0.001;
Table 2).
Factors associated with H-AECOPD length of stay
Including data from individuals admitted to hospital only (n = 291), multivariable analysis
identified multiple measures to be associated with H-AECOPD length of stay (Fig 2 and S8
Fig, S5 Table). All functional measures, except for QMVC were associated with a higher risk of
H-AECOPD stay. Age (IRR 1.83 per 10-year increase, 95% CI 1.48 to 2.26, p< 0.001), 6MWT
Fig 1. Associations of baseline musculoskeletal measures and rate of hospitalised acute exacerbation of chronic obstructive pulmonary disease in the ERICA
cohort. Risk indicated as incidence risk ratios. Estimates derived using negative binomial regression. Analyses adjusted for recruitment site. Age, sex, body mass index,
smoking status, forces expiratory volume in one second, phlegm, and exacerbation history were included as covariates. Figure displays standardised IRRs, allowing
comparison of measurements on different scales. Obs, number of observations included in analysis. IRR, incidence risk ratios. CI, confidence intervals. SD, standard
deviation. 6MWT, six-minute walk test. SPPB, short physical performance battery. 4MGS, four-metre gait speed. QMVC, quadriceps maximum voluntary contraction.
https://doi.org/10.1371/journal.pone.0228940.g001
Risk assessment for hospitalised AECOPD
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(IRR 1.14 per 30-metre decrease, 95% CI 1.08 to 1.20, p< 0.001), and SPPB (IRR 1.18 per 1
point decrease, 95% 1.10 to 1.27, p< 0.001) were the strongest associated variables.
Fully adjusted multivariable stepwise regression retained the following significant predic-
tors: age (IRR 1.53 per 10-year increase, 95% CI 1.18 to 1.98, p = 0.001), body mass index (IRR
0.93 per 1 point increase, 95% CI 0.90 to 0.96, p< 0.001), glucose (IRR 2.89 per twofold
increase, 95% CI 1.18 to 7.05, p = 0.020), and SPPB (IRR 1.19 per 1 point decrease, 95% CI
1.10 to 1.30, p< 0.001; Table 3).
Sensitivity analysis for rate of H-AECOPD
Overall, IRRs were higher for men and 6MWT for those with no exacerbation history (Table 2
and S6 Table). Incidence risk ratios of exacerbation history were higher for women when strat-
ifying by gender (Table 2 and S7 Table). When testing for interactions, both prior exacerbation
history and sex were significant.
Kaplan–Meier curves (Fig 3) according to SPPB tertiles demonstrated that reduced time to
first H-AECOPD was associated with higher SPPB or sit-to-stand scores (log-rank test for
trend: p = 0.032 and 0.008 respectively).
Discussion
In patients with stable COPD, we show that assessments of physical function including the
SPPB, and in particular the sit-to-stand component as a standalone, identify patients at risk of
H-AECOPD. Furthermore, barring age, the sit-to-stand is the strongest associated measure
that predicts length of stay for H-AECOPD. We additionally confirmed our prior findings,
that 6MWT predicts H-AECOPD in individuals with COPD after adjusting for common and
known predictive covariates. The only equipment required for the sit-to-stand test is a chair
and a stopwatch (an integral function on most smartphones) it can be performed virtually any-
where, and the test can be performed in less than five minutes. Therefore we propose that it
Table 2. Factors associated with rate of H-AECOPD in the stepwise multivariable model.
Multivariable analysisa Stepwise regression (n = 610)
Factors IRR (95% CI) IRR (95% CI) P value
Sex–male 2.41 (1.77 to 3.29) 2.14 (1.55 to 2.96) < 0.001
6MWT distance–per 30 metre decrease 1.13 (1.08 to 1.17) 1.08 (1.04 to 1.12) < 0.001
SPPB score–per 1 point decrease 1.08 (1.01 to 1.14) Omitted N/A
QMVC peak–per 1 kg decrease 1.02 (1.00 to 1.03) Omitted N/A
FEV1 –per 100 ml increase 0.84 (0.81 to 0.86) 0.88 (0.85 to 0.91) < 0.001
Exacerbation history (1 year),� 1b 1.94 (1.40 to 2.67) 1.96 (1.39 to 2.76) < 0.001
Fibrinogen–per 1 log unit increase 1.95 (1.03 to 3.68) Omitted N/A
Neutrophils–per 1 unit increase 1.14 (1.05 to 1.24) Omitted N/A
Resting heart rate–per 1 bpm increase 1.02 (1.01 to 1.03) 1.01 (1.00 to 1.03) 0.025
SGRQ-C–per 4 point increase 1.07 (1.03 to 1.10) Omitted N/A
CAT–per 1 point increase 1.05 (1.03 to 1.07) 1.03 (1.01 to 1.05) 0.010
Factors significantly associated with rate of H-AECOPD were included in the stepwise regression. Analyses were adjusted for recruitment site.
aAdjusted for age, sex, body mass index, smoking status, forced expiratory volume in one second, phlegm, and exacerbation history.
bSelf-reported prior to study.
IRR, incidence risk ratios. CI, confidence intervals. 6MWT, six-minute walk test. SPPB, short physical performance battery. QMVC, quadriceps maximum voluntary
contraction. FEV1, forced expiratory volume in one second. SGRQ-C, St George’s respiratory questionnaire for COPD. CAT, COPD assessment test.
https://doi.org/10.1371/journal.pone.0228940.t002
Risk assessment for hospitalised AECOPD
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may be a useful tool in both primary and secondary care for identification of patients at risk of
H-AECOPD as well as those that are likely to have a prolonged length of stay.
Fig 2. Associations of baseline musculoskeletal measures and hospital length of stay after admission for acute exacerbation of chronic obstructive pulmonary
disease in the ERICA cohort. Risk indicated as incidence risk ratios. Estimates derived using negative binomial regression. Analyses adjusted for recruitment site. Age,
sex, body mass index, smoking status, forces expiratory volume in one second, phlegm, and exacerbation history were included as covariates. Figure displays
standardised IRRs, allowing comparison of measurements on different scales. Obs, number of observations included in analysis. IRR, incidence risk ratios. CI,
confidence intervals. SD, standard deviation. 6MWT, six-minute walk test. SPPB, short physical performance battery. 4MGS, four-metre gait speed. QMVC, quadriceps
maximum voluntary contraction.
https://doi.org/10.1371/journal.pone.0228940.g002
Table 3. Factors associated with H-AECOPD length of stay in the stepwise multivariable model.
Multivariable analysisa Stepwise regression (n = 233)
Factor IRR (95% CI) IRR (95% CI) P value
Age–per 10 year increase 1.83 (1.48 to 2.26) 1.53 (1.18 to 1.98) 0.001
BMI–per 1 point increase 0.96 (0.93 to 0.99) 0.93 (0.90 to 0.96) < 0.001
6MWT distance–per 30 metre decrease 1.14 (1.08 to 1.20) Omitted N/A
SPPB–per 1 point decreaseb 1.18 (1.10 to 1.27) 1.19 (1.10 to 1.30) < 0.001
Exacerbation history (1 year),� 1c 0.62 (0.39 to 0.97) Omitted N/A
Glucose–per 1 log unit increase 8.78 (2.81 to 27.49) 2.89 (1.18 to 7.05) 0.020
Fibrinogen–per 1 log unit increase 3.14 (1.37 to 7.18) Omitted N/A
GFR–per 1 unit increase 0.98 (0.97 to 1.00) Omitted N/A
Factors significantly associated with H-AECOPD length of stay were included in the stepwise regression. Analyses were adjusted for recruitment site.
aAdjusted for age, sex, body mass index, smoking status, forced expiratory volume in one second, phlegm, and exacerbation history.
bWhen replacing SPPB with the sit-to-stand component both the sit-to-stand component and the 6MWT remain, but 6MWT is insignificant.
cSelf-reported prior to study.
IRR, incidence risk ratios. CI, confidence intervals. BMI, body mass index. 6MWT, six-minute walk test. SPPB = short physical performance battery. GFR, glomerular
filtration rate.
https://doi.org/10.1371/journal.pone.0228940.t003
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Fig 3. Time to first H-AECOPD estimates. (A) Estimates by SPPB tertiles. (B) Estimates by sit-to-stand tertiles.
https://doi.org/10.1371/journal.pone.0228940.g003
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Strengths of this study
This study has many strengths. Firstly, multiple functional measures were used simultaneously
in a large cohort of individuals clinically stable at assessment. Thus, although the importance
of physical performance has been previously reported for some of these assessments, this is the
first study to compare several of these tests and also comprehensively control for all other clini-
cal aspects of COPD. In addition, measurements were performed at five different sites across
the UK.
Secondly, event rates were stable throughout the study period, which is not only encourag-
ing but also rates were comparable to those in large cohort studies including ECLIPSE (Evalua-
tion of COPD Longitudinally to Identify Predictive Surrogate End-points)[16] suggesting that
the findings are generalisable outside the UK. Hospital admissions were identified using vali-
dated criteria, and only definite and possible episodes were included in the analysis. In contrast
to self-reported hospital admission, which may suffer from under-reporting,[17,18]
H-AECOPD episodes were captured objectively using electronic health record data. Individu-
als had different observation periods as a result of different entry times into the study. The use
of study inclusion and admission (i.e. event) dates allowed to adjust for exposure time and
therefore used the correct probability distributions.
Third, while previous exacerbation is an established predictor of exacerbation that can be
easily assessed, we also investigated factors associated with hospitalisation in patients without
exacerbation history. This is of interest since in patients with no previous exacerbation, the
predictors of an exacerbation are less well established. Lastly, collection of a comprehensive
data set permitted better adjustment for covariates than prior single centre studies.
Limitations of this study
Naturally this study has several limitations. Hospital Episode Statistics were obtained from the
NHS Digital (England), NHS Scotland and NHS Wales. Apart from admission and discharge
dates, we did not have spell data (i.e. total continuous stay and use of a hospital bed) available
for individuals registered with the NHS Scotland and NHS Wales. The study period covered
the time from study enrolment until the end of study, or death, and therefore the pre-enrol-
ment hospital use history could not be obtained from HES. The final number of individuals
included in the analysis were limited to those followed up by the NHS, slightly reducing the
statistical power.
The study size precluded stratification by gender to assess the association between baseline
measures and H-AECOPD stay (i.e. duration). Also, we explored for non-linearity of variables
considered but lacked statistical power to identify any difference. There were differences in
study populations between recruitment sites. For example, individuals from Cardiff were more
symptomatic (based on COPD impact scores); however we caution that the departments at
each of the five participating hospitals had variations in practice making analysis of difference
in prognosis between sites of doubtful value. Nevertheless, we addressed this by adjusting for
recruitment site in our analyses. There were missing data; in order to optimise the analysis, we
included as many observations as possible and reported the number of observations included
in each analysis.
Analyses were also adjusted for productive cough, believed to be an indicator of inflamma-
tion. A large proportion had productive cough on most mornings but there was no significant
association with the outcomes in our cohort (see supplementary tables).
Quadriceps maximum voluntary contraction was included in the study both because we
have previously found it to predict survival in COPD[19] and also because mechanistically it
could explain SPPB score.[20] The study did not confirm QMVC to be a measure that could
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have widespread uses despite being associated with a higher risk of H-AECOPD, since it was
not related to length of hospital stay. In addition, the test requires specialist equipment that is
bulky and not currently commercially available. However, the effect of the SPPB, and therefore
also QMVC, is potentially underestimated due to the relatively high SPPB mean score (10
points), with scores above ten indicating no functional limitation.
Meaning of this study
Our data suggest that the SPPB performed almost as well as the 6MWT for risk of H-AECOPD
while being more practical; moreover the sit-to-stand component in particular could be useful
as a standalone test in time-limited settings such as primary care with confidence since it was
not inferior to the SPPB. The good performance of SPPB was not entirely unexpected. In the
geriatrics literature, the SPPB is a well-established tool for predicting risk of admission to nurs-
ing home facilities. In a prior study, Kon et al. showed that one component of SPPB, the
4MGS, when measured at point of discharge for H-AECOPD, had a strong predictive value for
90-day readmission however that population has a strong pre-test probability of admission.
[21] In a similar population, Barker et al. reported that overall SPPB measured at point of dis-
charge following AECOPD was predictive of mortality risk.[22] In a study of 50 COPD
patients the sit-to-stand performance related to other prognostic scoring systems in COPD,
including the BODE score.[23]. In addition, the sit-to-stand component of the SPPB battery
has some similarities with the one minute sit-to-stand test which is predictive of mortality in
COPD.[24,25] However, the present study extends knowledge by showing that that the sit-to-
stand and the SPPB are associated both with admission risk and length of stay in stable COPD
outpatients, which is important for primary and secondary care. Importantly, no other study
provides data suggesting that in patients with stable COPD, SPPB or the sit-to-stand are associ-
ated with H-AECOPD incidence as well as related length of stay, and this information further
adds support for SPPB being used as a drug development tool and endpoint for clinical trials
addressing AECOPD, especially since the European Medicines Agency favours the SPPB as
the measure of choice in the assessment of frailty.[26] More recently, Hopkinson et al. empha-
sised the importance of considering individual risk factors such as exercise capacity, which
influences long term prognosis including hospital admission.[27]
Some treatments are presently available that can reduce the risk of exacerbation including
vaccination and optimisation of inhaled therapies, which it is increasingly recognised, should
be tailored to the individuals eosinophil status.[28] In addition, exercise-based treatments,
most notably pulmonary rehabilitation, can increase physical capacity.[29,30] Lastly although
the available data are mixed, some reports suggest that, at least in subsets of COPD patients,
novel strategies to deliver pulmonary rehabilitation can reduce re-admission rates and length
of stay by early application of telemedicine techniques.[31,32] All of these interventions have
costs and thus in terms of prioritising patients who will derive most benefit there is a need for
a stratification tool. Based on our findings we propose that the sit-to-stand component be
adopted as a routine measure in the care pathway for COPD patients, as its use can aid in iden-
tification of at-risk patients and thus aid resource planning.
Future studies
Future studies, using larger cohorts and/or different geographical populations, should replicate
our findings. In particular, when developing or evaluating a multivariable prognostic model,
the sample size should be estimated based on the D or C-statistic in order to sufficiently cap-
ture the significance of prognostic of specific biomarkers and produce robust estimates.[33] In
addition, evaluating these measures longitudinally would allow better estimation of the
Risk assessment for hospitalised AECOPD
PLOS ONE | https://doi.org/10.1371/journal.pone.0228940 February 10, 2020 11 / 16
association between H-AECOPD rate, duration, and readmission at different time points, as
well as estimation of a minimally important difference in COPD, the latter of which is cur-
rently lacking in literature.
Conclusions
Findings indicate that physical function including the SPPB, and in particular the sit-to-stand
component as a standalone test can both evaluate the risk of H-AECOPD and length of hospi-
tal stay in individuals with COPD. Moreover since sit-to-stand and SPPB can be performed
almost anywhere and without special equipment. Our data support the use of sit-to-stand or
SPPB to aid in clinical decision making at an individual level and when prioritising healthcare
resources, and support the incorporation of this tool into the annual COPD patient clinical
review.
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